Question special

Thank you everyone for this interesting discussion. I am very impressed by the significant reduction of the LDL cholesterol level by Evinacumab and excited to follow the results of a phase III trial comparing the drug with the standard of care treatment. When comparing the population clinical characteristics I noticed a significant difference between lipoprotein (a) levels between groups, especially in the subcutaneous group. Do you think that differences in the median of lipoprotein(a) levels may have any effect on the results?